Hydroxychloroquine does not counter SARS-CoV-2 in hamsters, high dose of favipiravir does
(KU Leuven) Virologists from the KU Leuven Rega Institute in Belgium have shown that a treatment with the anti-malaria drug hydroxychloroquine does not limit SARS-CoV-2 coronavirus replication in hamsters. A high dose of the anti-flu drug favipiravir, by contrast, has an antiviral effect in the hamsters. The team published their findings in the Proceedings of the National Academy of Sciences (PNAS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 9, 2020 Category: International Medicine & Public Health Source Type: news
Lopinavirritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, The Lancet
Summary Background Lopinavir –ritonavir has been proposed as a treatment for COVID-19 on the basis of in vitro activity, preclinical studies, and observational studies. Here, we report the results of a randomised trial to assess whether lopinavir–ritonavir improves outcomes in patients admitted to hospital with COVID-19. M ethods In this randomised, controlled, open-label, platform trial, a range of possible treatments was compared with usual care in patients admitted to hospital with COVID-19. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either usual s t...
Source: Current Awareness Service for Health (CASH) - October 6, 2020 Category: Consumer Health News Source Type: news
Hydroxychloroquine Not Beneficial for SARS-CoV-2 Preexposure Prophylaxis
TUESDAY, Oct. 6, 2020 -- Hydroxychloroquine administered for eight weeks as preexposure prophylaxis has no clinical benefit in hospital-based health care workers (HCWs) exposed to patients with COVID-19, according to a study published online Sept.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 6, 2020 Category: Pharmaceuticals Source Type: news
What to Know About Sean Conley, the White House Physician
Dr. Conley, who was appointed as President Trump ’s physician in 2018, is a doctor of osteopathic medicine. (Source: NYT Health)
Source: NYT Health - October 4, 2020 Category: Consumer Health News Authors: Allyson Waller and Christina Morales Tags: Trump Coronavirus Positive Result Hydroxychloroquine (Drug) United States Politics and Government Coronavirus (2019-nCoV) Reed, Walter, National Military Medical Center Conley, Sean Patrick Trump, Donald J Jackson, Ronny L Source Type: news
Trump-Touted Hydroxychloroquine Shows No Benefit in COVID-19 Prevention: Study Trump-Touted Hydroxychloroquine Shows No Benefit in COVID-19 Prevention: Study
The malaria drug did not show any benefit versus placebo in reducing coronavirus infection among healthcare workers, according to clinical trial results published on Wednesday.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - October 1, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news
Timeline: When Bad Research Changes Public Health Strategy
Illinois-based Surgisphere Corporation had a brief moment in the limelight this year following its infamous study of hydroxychloroquine. But the impact of the company ’s deception reverberated across... (Source: The Scientist)
Source: The Scientist - October 1, 2020 Category: Science Tags: Infographics Magazine Issue Source Type: news
Hydroxychloroquine no more effective than placebo in preventing COVID-19
(University of Pennsylvania School of Medicine) Clinical trial with COVID-19 testing of participants shows health care workers in contact with coronavirus patients who took hydroxychloroquine each day did not reduce their rate of infection. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 30, 2020 Category: Infectious Diseases Source Type: news
Efficacy, safety of hydroxychloroquine vs placebo to prevent SARS-CoV-2 infection among health care
(JAMA Network) In this randomized clinical trial, daily hydroxychloroquine didn't prevent SARS-CoV-2 infection among hospital-based health care workers, although the trial was terminated early. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 30, 2020 Category: Infectious Diseases Source Type: news
Trump-touted hydroxychloroquine shows no benefit in COVID-19 prevention: Study
The study largely confirms results from a clinical trial in June that showed hydroxychloroquine was ineffective in preventing infection among people exposed to the new coronavirus. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 29, 2020 Category: Pharmaceuticals Source Type: news
A New Look at Safety With Hydroxychloroquine in COVID-19 A New Look at Safety With Hydroxychloroquine in COVID-19
While a precipitous drop in use may make it almost moot, new data show only ' modest ' increases in QT prolongation and no arrhythmic deaths directly attributable to treatment.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 29, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
Hydroxychloroquine Tied to Heart Problems Prior to Pandemic
MONDAY, Sept. 28, 2020 -- Real-world, pre-COVID-19 adverse events data show hydroxychloroquine (HCQ) and chloroquine (CQ) are associated with cardiovascular adverse events (CVAEs), according to a study published online Sept. 22 in the British... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 28, 2020 Category: Pharmaceuticals Source Type: news
Where Docs, Nurses Stand on COVID Emergency Use Authorizations Where Docs, Nurses Stand on COVID Emergency Use Authorizations
Medscape polled clinicians on their thoughts after questions were raised about evidence the FDA used to grant emergency authorizations for hydroxychloroquine, convalescent plasma, and remdesivir.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - September 25, 2020 Category: Internal Medicine Tags: Infectious Diseases News Source Type: news
Extracorporeal treatment for chloroquine, hydroxychloroquine, and quinine poisoning: systematic review and recommendations from the EXTRIP Workgroup - Berling I, King JD, Shepherd G, Hoffman RS, Alhatali B, Lavergne V, Roberts DM, Gosselin S, Wilson G, Nolin TD, Ghannoum M, EXTRIP workgroup.
BACKGROUND: Although chloroquine, hydroxychloroquine, and quinine are used for a range of medical conditions, recent research suggested a potential role in treating COVID-19. The resultant increase in prescribing was accompanied by an increase in adverse e... (Source: SafetyLit)
Source: SafetyLit - September 25, 2020 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of preCOVID19 reports
This analysis of the FAERS database found use of hydroxychloroquine and chloroquine was associated with a higher reporting rate of major CV adverse events, including cardiomyopathy (reporting OR 29.0), QT prolongation (4.5), cardiac arrhythmias (2.2) and heart failure (2.2). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 24, 2020 Category: Consumer Health News Source Type: news
Discontinuation of Hydroxychloroquine in Older SLE Patients Discontinuation of Hydroxychloroquine in Older SLE Patients
Hydroxychloroquine is an effective treatment for SLE, but long-term use may increase the risk for adverse events. At what point should discontinuation be considered?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 23, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
